<DOC>
	<DOC>NCT01916980</DOC>
	<brief_summary>This is an efficacy and safety study of up to 12 weeks of desloratadine in Japanese participants with eczema/dermatitis and dermal pruritus. The primary hypothesis of this study is that the sum of the daytime and nighttime pruritus/itch scores for both the eczema/dermatitis group and the dermal pruritus group will be significantly improved at Week 2 compared to Baseline.</brief_summary>
	<brief_title>Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, seborrheic dermatitis, asteatotic eczema, neurodermatitis, etc. among eczema/dermatitis for which the observation of pruritus is appropriate) Dermal pruritus (generalized dermal pruritus, localized dermal pruritus) Hypersensitivity to antihistamines or ingredients of a study drug</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Dermatitis, Atopic</keyword>
	<keyword>Skin Diseases</keyword>
	<keyword>Skin Diseases, Genetic</keyword>
	<keyword>Genetic Diseases, Inborn</keyword>
	<keyword>Skin Diseases, Eczematous</keyword>
	<keyword>Hypersensitivity, Immediate</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>